MRUS MERUS B V

Merus to Participate in Upcoming Investor Conferences

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the following investor conferences:

  • Guggenheim 6th Annual Biotechnology Conference: Wednesday, February 7, 2024 at 2:30 p.m. ET
  • Citi’s 2024 Oncology Leadership Summit: Thursday, February 22, 2024 at 9:00 a.m. ET

The webcasts of the presentations will be contemporaneously available on the of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus

is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as . Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit and .

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:
Sherri Spear
Merus N.V.
VP Investor Relations and Corporate Communications
617-821-3246
 

Kathleen Farren
Merus N.V.
IR/Corp Comms
617-230-4165
EN
31/01/2024

Underlying

MRUSMERUS B V

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MERUS B V

Thomas Vranken
  • Thomas Vranken
MRUS MERUS B V

Merus Updated ASCO data confirm best-in-class potential in 1L HNSCC

Merus reported solid interim Ph2 data for ASCO 2025 with peto combo with Keytruda in 1L PD-L1+ r/m HNSCC, tracking nicely in line with last year's ASCO data. The updated dataset featured a 63% ORR (incl. 6 CRs), a mPFS of 9 months, and 12-month survival rate of 79%. Responses were observed across PD-L1 levels and HPV+ subgroups, and the treatment showed no new safety signals. The data support petosemtamab's potential to outperform Keytruda monotherapy and become the new gold standard in head an...

2h / 45m 2h / 45m 1 EN
Guy Sips ... (+5)
  • Guy Sips
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
MRUS MERUS B V
SPEC SMARTPHOTO GROUP
AKZA AKZO NOBEL N.V.
7h / 2m 7h / 2m 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robus...

Merus’ Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC -  63% response rate observed among 43 evaluable patients -  79% overall survival rate at 12-months; 9 months median progression-free survival -  Conference Call on Thursday, May 22 at 5:30 p.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and A...

16h / 27m 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus gibt die Veröffentlichung des Wirkmechanismus von Petosemtamab i...

Merus gibt die Veröffentlichung des Wirkmechanismus von Petosemtamab in der Fachpresse bekannt UTRECHT, Niederlande, und CAMBRIDGE, Massachusetts, May 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) („Merus“, „das Unternehmen“, „wir“ oder „unser“), ein Onkologieunternehmen, das innovative, multispezifische Antikörper und Antikörper-Wirkstoff-Konjugate (Biclonics®, Triclonics® und ADClonics®) in voller Länge entwickelt, hat heute die Veröffentlichung des Wirkmechanismus von Petosemtamab, einem bispezifischen Antikörper gegen den epidermalen Wachstumsfaktor-Rezeptor (EGFR) und Leucin-Rich G (L...

May 16, 2025 1 EN
 PRESS RELEASE
Free
MRUS MERUS B V

Merus annonce la publication d’un article sur le mécanisme d’action du...

Merus annonce la publication d’un article sur le mécanisme d’action du pétosemtamab UTRECHT, Pays-Bas et CAMBRIDGE, État du Massachusetts, 16 mai 2025 (GLOBE NEWSWIRE) -- (Nasdaq : MRUS), ci-après « Merus », « la Société », « nous » ou « notre/nos », une société d’oncologie au stade clinique développant des anticorps multispécifiques de pleine longueur innovants et des conjugués anticorps-médicaments (Biclonics®, Triclonics® et ADClonics®), annonce aujourd’hui la parution d’un article sur le mécanisme d’action du pétosemtamab, un anticorps bispécifique ciblant le récepteur du facteur de ...

May 16, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch